Intensity-modulated radiotherapy for localized nasopharyngeal amyloidosis

Luo, Ming; Peng, Gang; Shi, Liangliang; Ming, Xing; Li, Zhenyu; Fei, Shijiang; Ding, Qi; Cheng, Jing

doi:10.1007/s00066-016-0996-6

Cited by 15 publications

(9 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A positive effect of LD-RT on amyloid load was previously reported in patients presenting peripheral amyloidosis [30][31][32][33][34][35][36] and recently in three AD mouse models [15][16][17]. Nevertheless, this reduction of the number of amyloid plaques was not observed in our rat model.…”

Section: Discussionsupporting

confidence: 40%

Treatment by Low-Dose Brain Radiation Therapy Improves Memory Performances without Changes of the Amyloid Load in the TgF344-AD Rat Model.

Ceyzériat¹,

Zilli²,

Fall³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background. Alzheimer’s disease (AD) is a neurodegenerative condition affecting memory performance. This pathology is characterized by intracerebral amyloid plaques and tau tangles coupled with neuroinflammation. During the last century, numerous therapeutic trials, targeting amyloid, tau or neuroinflammation, unfortunately failed. Development of new therapeutic approaches for AD is eagerly awaited. In this study, we propose to test the use of low-dose brain radiotherapy (LD-RT). LD-RT showed efficacy to reduce amyloid load in patients with peripheral pathologies and also presents anti-inflammatory effects in patients with systemic inflammatory diseases. Furthermore, previous evidence showed an effect on amyloid load, memory performance and modulation of the immune response in AD mice. Methods. The hemi-brain of 14-15 months old TgF344-AD rats was irradiated with two LD-RT schedules (5 fractions of 2 Gy, delivered weekly or daily). Rats underwent behavioral tests to assess memory and general locomotion, before and/or 4 months post treatment. LD-RT impact on amyloid and neuroinflammation was measured using immunohistology.Results. An improvement of spatial working memory was observed in the daily treated group but not in animals treated weekly. On the other hand, both LD-RT schedules were unable to impact amyloid load. An increase of astrocyte reactivity was observed in TgAD groups compared to wild-type animals but LD-RT did not impact it. The weekly treatment increased CD68+ microglial density in the molecular layer of the hippocampus but no effect was observed with the daily treatment. One major limitation of this study was the already well-established amyloid pathology, which was probably too advanced to observe a potential decrease. Nevertheless, we observed a memory improvement, the main cognitive symptoms of AD, after daily treatment, offering encouraging data to further evaluate the LD-RT therapeutic potential. Conclusions. This study showed a biological effect of LD-RT in an AD rat model on memory performance (after daily treatment) and microglial density (after weekly treatment). The lack of effect of both regimens on amyloid pathology, unexpected, was possibly due to the advanced pathology of our animals. The positive effect on cognition encourages to further evaluate the LD-RT therapeutic potential at an earlier AD stage.

show abstract

Section: Discussionsupporting

confidence: 40%

Treatment by Low-Dose Brain Radiation Therapy Improves Memory Performances without Changes of the Amyloid Load in the TgF344-AD Rat Model.

Ceyzériat¹,

Zilli²,

Fall³

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…Surgical debridement of the involved sinonasal compartments provides symptomatic benefits in most of the cases and in some cases can impart long recurrence free intervals, however, recurrence tends to occur in more than 50% of cases, which may necessitate revision surgery [3]. In cases of localized laryngeal, tracheobronchial and nasopharyngeal amyloidosis, radiotherapy has been used but the results have not been consistent and the appropriate dose to be delivered remains undefined [11]. The rarity of the condition and unpredictable course of the disease makes it difficult to frame a definitive treatment algorithm and symptomatic treatment with surgical debridement remains the realistic goal at present.…”

Section: Discussionmentioning

confidence: 99%

Idiopathic Isolated Nasal Amyloidosis: Report of a Rare Case with Review of Literature

Singh

Handa

Kumar

2018

Indian J Otolaryngol Head Neck Surg

View full text Add to dashboard Cite

Deposition of amyloid in localized form is rare and most often involves head and neck region. Localized amyloidosis carries good prognosis with surgical debridement offering symptomatic benefit. We present an adolescent male presenting with localized sinonasal amyloidosis managed previously with conservative surgical debridement. The patient was symptomatic from early childhood and the previous histopathological reports were non-specific inflammation. A repeat biopsy revealed features of amyloidosis and retrospective review of past slides revealed the same. On explaining the course of the disease and prognosis, the patient opted for regular follow up. A pertinent comprehensive literature review of the condition is discussed.

show abstract

“…We confirm the effectiveness of radiotherapy, particularly in combination with surgical debulking, in selected cases. [17][18][19] However, in general we observed no differences in outcome according to different treatment regimens.…”

Section: Discussionmentioning

confidence: 54%

Localized immunoglobulin light chain amyloidosis: Novel insights including prognostic factors for local progression

et al. 2020

View full text Add to dashboard Cite

In localized light chain amyloidosis (locAL), amyloidogenic light chains (aLC) are produced and deposited locally by a B‐cell clone. We present 293 patients with immunohistochemically confirmed locAL. Lung (nodular pulmonary) with 63 patients was the most involved organ. The aLC was λ in 217 cases (κ:λ ratio 1:3). A local B‐cell clone was identified in 30% of cases. Sixty‐one (21%) had a concomitant autoimmune disorder (cAD). A monoclonal component (MC) were present in 101 (34%) patients and were more frequent in subjects with cAD (51% vs 34%; P = .03). Cigarette smoking was more prevalent in lung locAL (54% vs 37%; P = .018). After a median follow‐up of 44 months, 16 patients died and 5‐ and 10‐years locAL progression‐free survival (PFS) were 62% and 44%. Interestingly, locAL‐PFS was shorter among patients with an identified clonal infiltrate at amyloid deposition site (40 vs 109 months; P = .02) and multinuclear giant cells and/or an inflammatory infiltrate resulted in longer locAL‐PFS in lung involvement (65 vs 42 months; P = .01). However, no differences in locAL PFS were observed in patients with cAD, a MC and involved organ site. Treatment was administered in 163 (54%) patients and was surgical in 135 (46%). Median locAL‐PFS after first treatment was 56 months. Responders had longer locAL‐PFS (78 vs 17 months; P < .001). Three patients with lung locAL and a MC were diagnosed as systemic AL amyloidosis at follow‐up. In summary, locAL pathogenesis seems to be heterogeneous and the clonal infiltrate leads local progression.

show abstract

Intensity-modulated radiotherapy for localized nasopharyngeal amyloidosis

Cited by 15 publications

References 39 publications

Treatment by Low-Dose Brain Radiation Therapy Improves Memory Performances without Changes of the Amyloid Load in the TgF344-AD Rat Model.

Treatment by Low-Dose Brain Radiation Therapy Improves Memory Performances without Changes of the Amyloid Load in the TgF344-AD Rat Model.

Idiopathic Isolated Nasal Amyloidosis: Report of a Rare Case with Review of Literature

Localized immunoglobulin light chain amyloidosis: Novel insights including prognostic factors for local progression

Contact Info

Product

Resources

About